Catalyst Wire Dossier Catalyst Wire Dossier

Efpegerglucagon

HM15136 · Hanmi Pharmaceutical Company Limited
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Efpegerglucagon, covering 2025-02-21 to 2025-02-21. Get the full timeline:

Most recent: Clinical Trial Update: HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) [Phase 2]

See pricing